A Convalife Pharmaceuticals Co. Ltd. and Zhejiang Convalife Pharmaceutical Co. Ltd. patent describes new complement factor B (CFB) inhibitors potentially useful for the treatment of IgA nephropathy, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, age-related macular degeneration, cardiovascular disorder and cancer.